These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 3791495)

  • 1. Structural studies of a new dihydropyridine calcium channel antagonist, nilvadipine.
    Miyamae A; Koda S; Morimoto Y
    Chem Pharm Bull (Tokyo); 1986 Aug; 34(8):3071-8. PubMed ID: 3791495
    [No Abstract]   [Full Text] [Related]  

  • 2. Determination of nilvadipine in plasma and urine by capillary column gas chromatography with electron-capture detection.
    Tokuma Y; Fujiwara T; Sekiguchi M; Noguchi H
    J Chromatogr; 1987 Mar; 415(1):156-62. PubMed ID: 3584351
    [No Abstract]   [Full Text] [Related]  

  • 3. Physico-chemical properties and stabilities of the highly potent calcium antagonist benidipine hydrochloride.
    Suzuki H; Ono E; Ueno H; Takemoto Y; Nakamizo N
    Arzneimittelforschung; 1988 Nov; 38(11A):1671-6. PubMed ID: 3219139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of nilvadipine, a new dihydropyridine-type calcium antagonist.
    Honerjäger P; Seibel K
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S15-21. PubMed ID: 1283184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective oxidation and plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man.
    Niwa T; Tokuma Y; Nakagawa K; Noguchi H; Yamazoe Y; Kato R
    Res Commun Chem Pathol Pharmacol; 1988 May; 60(2):161-72. PubMed ID: 3393731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of the dihydropyridines, 3-(2-furoyl)-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)- 1,4-dihydropyridine and nifedipine, by high-performance liquid chromatography with electrochemical detection.
    Huebert ND; Spedding M; Haegele KD
    J Chromatogr; 1986 Feb; 353():175-80. PubMed ID: 3754560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man and dog.
    Niwa T; Tokuma Y; Noguchi H
    Res Commun Chem Pathol Pharmacol; 1987 Jan; 55(1):75-88. PubMed ID: 3563108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nilvadipine: profile of a new calcium antagonist. An overview.
    Rosenthal J
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S92-107. PubMed ID: 7898101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. X-ray crystallographic characterization of nilvadipine monohydrate and its phase transition behavior.
    Hirayama F; Honjo M; Arima H; Okimoto K; Uekama K
    Eur J Pharm Sci; 2000 Jul; 11(1):81-8. PubMed ID: 10913756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational features of calcium channel agonist and antagonist analogs of nifedipine.
    Langs DA; Triggle DJ
    Mol Pharmacol; 1985 May; 27(5):544-8. PubMed ID: 2581123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photochemical stabilities of some dihydropyridine calcium-channel blockers in powdered pharmaceutical tablets.
    Kawabe Y; Nakamura H; Hino E; Suzuki S
    J Pharm Biomed Anal; 2008 Jul; 47(3):618-24. PubMed ID: 18339506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Amlodipine: pharmacokinetic and pharmacodynamic profile of a calcium antagonist with prolonged effect].
    Heynen G
    Schweiz Rundsch Med Prax; 1992 Feb; 81(7):199-203. PubMed ID: 1531545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectroscopic and HPLC studies of photodegradation of nilvadipine.
    Augustyniak W; Mielcarek J; Milewski M; Szamburska O
    Drug Dev Ind Pharm; 2001 Nov; 27(10):1031-8. PubMed ID: 11794805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina.
    Brogden RN; McTavish D
    Drugs Aging; 1995 Feb; 6(2):150-71. PubMed ID: 7711361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New dihydropyridine drug, nilvadipine, blocks the calcium slow action potential in rat-cultured aortic smooth muscle cells.
    Bkaily G; Molyvdas PA; Ousterhout J; Sperelakis N
    Eur J Pharmacol; 1986 May; 124(1-2):59-65. PubMed ID: 3720845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and calcium channel antagonist activity of 1,2-dihydropyridyl analogues of nifedipine.
    Wynn H; Ramesh M; Matowe WC; Wolowyk MW; Knaus EE
    Drug Des Deliv; 1988 Nov; 3(3):245-56. PubMed ID: 2855579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of nilvadipine against glutamate neurotoxicity in purified retinal ganglion cells.
    Otori Y; Kusaka S; Kawasaki A; Morimura H; Miki A; Tano Y
    Brain Res; 2003 Jan; 961(2):213-9. PubMed ID: 12531488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative structure-activity relationships for 1,4-dihydropyridine calcium channel antagonists (nifedipine analogues): a quantum chemical/classical approach.
    Gaudio AC; Korolkovas A; Takahata Y
    J Pharm Sci; 1994 Aug; 83(8):1110-5. PubMed ID: 7983594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of nilvadipine in human plasma by capillary column gas chromatography-negative-ion chemical-ionization mass spectrometry.
    Tokuma Y; Fujiwara T; Noguchi H
    J Chromatogr; 1985 Nov; 345(1):51-8. PubMed ID: 4086588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of calcium channel entry blockers, nifedipine and nilvadipine, on colonic motor activity.
    Barone FC; White RF; Ormsbee HS; Wasserman MA
    J Pharmacol Exp Ther; 1986 Apr; 237(1):99-106. PubMed ID: 2420971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.